Cathie Wood Doubles Down on Nvidia: Dumps Circle After IPO Surge
June 17 - Cathie Wood's ARK Invest made high-conviction moves on Monday, scooping up shares of tech titans while cutting ties with a buzzy new listing, signaling a sharpened focus on long-term innovation bets.
Warning! GuruFocus has detected 4 Warning Signs with NVDA.
The ARK Innovation ETF (ARKK) snapped up 128,163 shares of Nvidia (NASDAQ:NVDA), worth roughly $18.5 million. The buy comes as investors cheer Nvidia's AI roadmap and CEO Jensen Huang's upbeat commentary on quantum computing. Huang also confirmed the chipmaker will no longer factor China into future forecasts, reinforcing its pivot to less geopolitically sensitive markets.
ARK also increased its exposure to DoorDash (NASDAQ:DASH) and nuclear tech player BWX Technologies (NYSE:BWXT), building positions in companies riding sector-specific tailwinds.
In a surprising reversal, Wood trimmed a large chunk of her Circle Internet Group (NYSE:CRCL) stake, a stock she aggressively bought during its IPO. Despite Circle rallying over 13% on the day, ARK appears to be locking in early gains and reallocating capital to higher-conviction names.
The fresh round of Nvidia buying underscores Wood's continued confidence in next-gen computing, even as chip stocks wrestle with tightened U.S. export curbs. The shake-up signals ARK's strategy is doubling down on future-focused growth, while shedding names that may no longer fit the thesis.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Reliance Global Group Signs Letter of Intent to Sell Fortman Insurance for $5 Million in Cash
Transaction highlights strategic execution and unlocks capital for highly accretive Spetner Acquisition LAKEWOOD, NJ, June 17, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) ('Reliance,' 'we,' 'us,' 'our' or the 'Company') today announced it has signed a non-binding Letter of Intent (LOI) to sell Fortman Insurance Agency ('Fortman'), a wholly owned subsidiary for $5 million in cash. The contemplated sale price represents a meaningful premium over the original acquisition cost, underscoring the Company's ability to acquire, improve, and opportunistically monetize assets to drive shareholder value. Since acquiring Fortman, Reliance has implemented operational enhancements, upgraded internal systems, and established a strong leadership team. As a result, Fortman has evolved into a well-capitalized, efficiently run agency with a growing customer base and enhanced market presence. Ezra Beyman, CEO of Reliance, commented, 'The potential sale of Fortman demonstrates our disciplined capital allocation strategy and commitment to value creation. We acquired Fortman at a compelling valuation, strengthened its operations, and are now positioned to realize a meaningful return. This contemplated transaction reflects our ability to execute and supports our broader goal of building a highly profitable and focused organization. Not only does the sale price represent a premium to what we paid for Fortman, but it also adds substantial cash to our balance sheet—an especially notable achievement in light of our current market capitalization. We believe that this highlights the substantial underlying value embedded across our broader portfolio.' Proceeds from the sale are expected to support Reliance's planned acquisition of Spetner Associates ('Spetner'), a rapidly growing and synergistic insurance platform. As highlighted in previous announcements, Spetner has experienced robust growth in recent years and is expected to generate strong cash flow at both the subsidiary and parent company levels. The Company believes Spetner will integrate seamlessly into Reliance's operations under the OneFirm strategy. 'By monetizing Fortman at a premium, we are building internal cash reserves that are intended to advance the Spetner acquisition,' added Beyman. 'This strategy reflects our commitment to enhancing shareholder value while pursuing transformative and accretive growth opportunities. We believe replacing our Fortman subsidiary with Spetner aligns with our long-term vision for scale, synergy, and sustained cash flow generation.' The LOI is non-binding and subject to customary due diligence and negotiation of definitive documentation. The Company will provide additional updates as the transaction progresses. About Reliance Global Group, Inc. Reliance Global Group, Inc. (NASDAQ: RELI) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company's business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company's business-to-consumer platform, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail 'brick and mortar' insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products. Further information about the Company can be found at Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by terminology such as 'may,' 'should,' 'could,' 'would,' 'will,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'continue,' 'potential,' and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding: Our ability to complete the non-binding Letter of Intent to sell Fortman Insurance Agency for $5 million and to realize the contemplated premium over our original acquisition cost; Our plans to deploy the proceeds from the Fortman sale for the proposed acquisition of Spetner Associates, Inc.; Our expectation that the Spetner acquisition will close on commercially reasonable terms and receive any required regulatory and shareholder approvals; Our objectives to continue acquiring, improving and opportunistically monetizing agency-level assets to drive shareholder value; Our intentions to pursue disciplined, accretive growth opportunities in the InsurTech and insurance agency industries; and Other statements of our plans, objectives, expectations and intentions with respect to future operations, financial results, products and services. These forward-looking statements are based on a number of assumptions, including the assumptions that: the LOI will not be terminated prior to execution of definitive purchase agreements; due diligence and documentation negotiations will proceed without material adverse findings; the Fortman sale and the Spetner acquisition will both close as expected; our revenue and EBITDA projections for Spetner are attainable; integration risks will be managed successfully; and there will be no material adverse changes in market, economic or regulatory conditions affecting our businesses. There can be no assurance that any of these assumptions will prove correct. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These include, among others: the risk that the Fortman buyer may withdraw or renegotiate the terms of the LOI; delays or failure to complete either the Fortman sale or the Spetner acquisition; unanticipated liabilities or integration challenges in connection with Spetner; our inability to realize the projected revenue or EBITDA benefits; competition in the InsurTech and agency brokerage industry; changes in insurance regulation or Nasdaq listing requirements; general economic or financial market conditions; and the other risks and uncertainties described in the 'Risk Factors' section of our Registration Statement on Form S-1 and our periodic reports filed with the Securities and Exchange Commission. You should carefully review our Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and the other reports we have filed or will file with the SEC for a more complete discussion of risks and uncertainties. Except as required by law, Reliance Global Group, Inc. disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact:Crescendo Communications, LLCTel: +1 (212) 671-1020Email: RELI@
Yahoo
36 minutes ago
- Yahoo
Toll Brothers Announces New Luxury Home Community Coming Soon to Argyle, Texas
ARGYLE, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced its newest community, Enclave at Hickory Hill, is coming soon to Argyle, Texas. This exclusive Dallas-area community will feature new luxury homes on spacious one-acre home sites, offering an exceptional living experience in Denton County. Site work is underway, and the community is anticipated to open for sale in fall 2025. Enclave at Hickory Hill combines convenience with rustic elegance, offering an array of one- and two-story home designs ranging from 3,700 to over 6,000 square feet. Homes will feature 4 to 5 bedrooms, 3.5 to 6 bathrooms, and 3-car garages with options for 4-car garages. Each home will be built with the outstanding quality, craftsmanship, and value for which Toll Brothers is known. Toll Brothers homes in Enclave at Hickory Hill will be priced from $1.7 million. Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.'We are excited to introduce Enclave at Hickory Hill, where home shoppers can discover the perfect blend of luxury and tranquility in a prime Argyle location,' said Jay Saunders, Division President of Toll Brothers in Dallas. 'With spacious home sites and exceptional home designs, this community will offer an unparalleled lifestyle for our customers.'Residents of Enclave at Hickory Hill will benefit from its proximity to major commuter routes including Interstate 35 and Highway 377, providing easy access to surrounding areas. The community is situated within the esteemed Argyle Independent School District, with students attending Hilltop Elementary, Sixth Grade Center, Argyle Middle, and Argyle High School. Nearby shopping, entertainment, and dining opportunities can be found in Highland Village and Flower Mound, making Enclave at Hickory Hill an ideal location for those seeking both convenience and luxury. For more information and to join the Toll Brothers interest list for Enclave at Hickory Hill, call (855) 289-8656 or visit About Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@ Photos accompanying this announcement are available at: Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Company Announcement contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. Company Announcement no. 34CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 170625_CA34_Managerial Employee Transactions_FINALSign in to access your portfolio
